Can MK-677 Make You Taller? What the Human Research Actually Shows

Main ideas / lessons

• MK-677 (a growth-hormone secretagogue) is not proven to increase height after growth plates close.
• Height increase depends primarily on whether growth plates still have remaining “growth potential,” not on how much growth hormone (GH) or IGF-1 you can raise.
• If growth plates are open, MK-677’s effect on height is theoretically plausible (because it raises GH and IGF-1), but human evidence for actual height gain is missing.
• Cortisol is raised by MK-677 and may counteract growth—especially in younger people, where cortisol is described as anti-growth (catabolic).
• Even when height changes are reported anecdotally, it’s unclear whether it’s true acceleration vs. natural growth timing.
• Risks of increasing GH activity in children may include orthopedic complications (not specific to MK-677, but relevant to growth-plate stimulation in general).
• Metabolic side effects (blood sugar/insulin) are discussed as a concern, and the speaker claims personal mitigation via a specific supplement.

---

Methodology / structure of claims (as presented)

The speaker’s “hypothesis testing” approach

• Hypothesis
  • If GH causes children to grow taller, and MK-677 raises GH, then MK-677 should increase height.
• Key deciding factor
  • Whether the subject still has remaining growth plate cell divisions (i.e., growth plates open vs. closed).
• Additional factor introduced
  • A “cortisol counterbalance”: MK-677 increases cortisol, which may reduce net growth.

Evidence types the speaker uses

1. Clinical trial evidence for real GH therapy
   • Used as a benchmark for “what height change is realistically possible” when growth plates are open.
2. Pharmacology evidence that MK-677 affects GH/IGF-1
   • Adult 1-year trial: increased GH/IGF-1 signaling.
   • Limited pediatric MK-677 study: increased IGF-1, but no height measurement.
3. Biology of growth plates
   • Growth plates act like a countdown; hormones don’t restart remaining cell divisions once finished.
4. Animal evidence
   • Rats showed no increase in body/bone length in a 6-week experiment; the effect reportedly “stopped,” possibly due to feedback regulation.
5. Risk extrapolation from large GH prescriptions in children
   • Even if growth stimulation helps, increased stimulation may raise the risk of growth-plate-related orthopedic injuries.

---

Detailed bullet points of the main findings / reasoning

1) Does MK-677 make people taller?

• If growth plates are closed (adult/full height)
  • The speaker’s conclusion is no—no dosage will make someone taller because growth plates have completed growth cycles.
• If growth plates are open (adolescence)
  • The speaker claims no scientifically proven human answer for height gain.
  • The speaker states that the available pediatric MK-677 study(s) did not measure height.

2) Real-world framing from the speaker

• Personal/anecdotal observation:
  • The speaker reports:
    • Not taller
    • Wider/thicker (hands/feet and more muscular tissue)
• Suggested explanation:
  • GH/IGF-1 may still affect other tissues even if height growth is no longer possible.

3) Benchmark: height increase from actual GH therapy

• Short kids trial (placebo-controlled)
  • What was measured: adult height after long-term treatment
  • Result claimed: Children given real growth hormone ended up 3.7 cm taller than placebo after 4.4 years
  • Key takeaway: Even when GH works clinically, the height increase is modest and requires years of injections and high cost.

4) MK-677’s biological plausibility (GH/IGF-1 changes)

• Adult MK-677 (1-year) trial findings claimed
  • GH rose to ~1.8×
  • IGF-1 rose to ~1.5×
  • Effect reportedly persisted across the year
• Pediatric MK-677 (7-day) study findings claimed
  • 18 children who were growth hormone deficient, before puberty
  • IGF-1 increased
  • No child height outcomes were measured due to the short timeframe
  • Authors allegedly suggested readiness for future height testing, but the speaker says follow-up height trials were never published.

5) Why height trials might not exist (as argued by speaker)

• The speaker’s rationale is described as primarily financial/competitive:
  • GH injectables are prescription products with strong commercial incentives.
  • If MK-677 could replace or outperform GH, profits could be threatened.
  • Therefore, the speaker claims it’s unlikely that incentive-aligned parties would fund trials that might undermine their market.

6) Growth plate “mechanism” emphasized

• Growth plates contain cartilage with a fixed number of cell divisions.
• Growth hormone/IGF-1 can stimulate growth while plates remain active, but:
  • hormones don’t control the countdown
  • once growth potential is consumed, growth plates close and height growth stops
• Therefore: more GH after closure doesn’t create new growth-plate capacity.

7) Nutritional deficiency hypothesis (speaker’s added interpretation)

• In contexts with nutritional deficiencies (e.g., protein deficiency):
  • people may be shorter than their genetic potential
  • GH-pathway signaling like IGF-1 can rise with better nutrition
  • GH-related therapies could bring people closer to expected height
• However, this does not override the adult rule about growth-plate closure.

8) Animal and human nuance

• Rat study (6 weeks)
  • Claimed no increase in:
    • body length
    • bone length
    • growth plate width
  • Claimed MK-677 effect “stopped” due to feedback loop changes in rats (vs. humans where GH/IGF-1 effects continued for a year)
  • Speaker argues that better experimental design might be needed (e.g., cycling), but it wasn’t done
• Study in young healthy men
  • Claimed total GH over the day didn’t increase
  • Speaker’s explanation: those men may already have high GH production (adolescence-like pattern), leaving little measurable “increase”
  • Speaker also claims their own supervision:
    • 20 mg MK-677 produced GH exposure (area under the curve) comparable to 5 IU pharmaceutical-grade GH in ages 22–45
    • effects in both men and women were discussed
  • Speaker notes these are not phase 3 clinical studies and may not become widely validated.

9) Cortisol counterbalance (major differentiator)

• The speaker states the 1-year MK-677 trial showed increased cortisol.
• Cortisol is described as:
  • catabolic (breaks down tissue)
  • anti-growth in children (opposes taller growth)
• Conclusion offered:
  • If MK-677 increases GH/IGF-1 but also increases cortisol, net height gain could be reduced unless cortisol is lowered.

10) Example case: a 17-year-old reported to grow ~an inch quickly

• Speaker reports observing:
  • a 17-year-old growing ~1 inch in <3 months
• Main uncertainty:
  • unknown whether this would have happened anyway naturally
  • late-teen growth may be approaching final height
  • the growth could be accelerated rather than increasing total lifetime height
• Cortisol-lowering interventions:
  • the reported 17-year-old allegedly did not use cortisol-lowering interventions, so outcomes under cortisol reduction are unknown
• Quantitative context claimed:
  • At 17 years old, the average boy is said to be at 97.6% of final adult height (about 4 cm left, i.e., ~1.5 inch)
  • Therefore, the observed inch might fit within normal remaining growth.

11) Final “where we land” recommendations/claims

• If growth plates are closed: MK-677 won’t make you taller.
• If growth plates are open: the mechanism suggests a possible effect, but human confirmation for height is absent (per speaker’s stated evidence gaps).
• Timing estimate provided by speaker:
  • For many men, growth plates close approximately ages 16–19
  • bone age matters more than chronological age

12) Caution: orthopedic risk from GH stimulation in children

• Warning: increasing GH activity in children can cause:
  • slipped growth-plate-related injuries (“slip out of position”)
  • potentially requiring surgery
• Speaker cites:
  • a large study (~36,000 children) on prescription growth hormone (not MK-677) where:
    • risk of joint slipping was 3.5× higher
    • risk increased with longer treatment duration
• Key caution framing:
  • the tissue targeted for height gain can also be injured if overstimulated.

13) Blood sugar / insulin side effects and mitigation claim

• Speaker acknowledges a common concern:
  • MK-677 may worsen blood sugar/insulin dynamics
• Personal mitigation claim:
  • When the speaker used MK-677, they also used “Slin Pills” (a product they claim they helped design)
  • They state they observed:
    • no rise in blood sugar on MK-677
    • no loss of insulin sensitivity
  • They interpret this as fully negating those side effects.

---

Speakers / sources featured

Speaker(s)

• Unidentified speaker/creator (narrator; speaks in first person about personal experiments and supervising research)

Sources / studies named or referenced

• Journal of Clinical Endocrinology and Metabolism (2004)
  • “Short kids trial” / placebo-controlled growth hormone study; followed children 4.4 years to adult height; result claimed 3.7 cm
• Clinical Pharmacology and Therapeutics (2001)
  • “7-day study” of MK-677 in 18 growth-hormone-deficient children before puberty; measured IGF-1 increase but not height
• 1-year MK-677 trial in adults
  • claimed increased GH (~1.8×) and IGF-1 (~1.5×) and increased cortisol
• Rat study
  • 6-week MK-677 experiment; reportedly no increase in body/bone length or growth plate width; effect reportedly “stopped” (feedback loop explanation)
• Study in young healthy men
  • claimed total GH over the day did not increase (speaker explains as possibly due to already-high baseline GH)
• Large prescription GH study (~36,000 children)
  • joint slipping risk 3.5× higher, increasing with longer treatment duration
• “FDA trials” / “phase 3 clinical studies”
  • referenced generally (no specific trial name provided)